Page 179 - 磁共振成像2024年7期电子刊
P. 179

综   述||Reviews                       磁共振成像  2024年7月第15卷第7期  Chin J Magn Reson Imaging, Jul, 2024, Vol. 15, No. 7


              23685.                                           [63] JIANG S, GUO P, HEO H Y, et al. Radiomics analysis of amide proton
           [49] FU  J,  SINGHRAO  K,  ZHONG  X  R,  et  al.  An  automatic  deep   transfer-weighted  and  structural  MR  images  for  treatment  response
              learning-based  workflow  for  glioblastoma  survival  prediction  using   assessment  in  malignant  gliomas[J/OL].  NMR  Biomed,  2023,  36(1):
              preoperative  multimodal  MR  images:  A  feasibility  study[J/OL].  Adv   e4824  [2024-03-04].  https://pubmed. ncbi. nlm. nih. gov/36057449/.  DOI:
              Radiat Oncol, 2021, 6(5): 100746 [2024-03-04]. https://pubmed.ncbi.nlm.  10.1002/nbm.4824.
              nih.gov/34458648/. DOI: 10.1016/j.adro.2021.100746.  [64] ZHANG  J,  WU Y,  WANG Y,  et  al.  Diffusion-weighted  imaging  and
           [50] NIE D, LU J, ZHANG H, et al. Multi‐channel 3D deep feature learning   arterial  spin  labeling  radiomics  features  may  improve  differentiation
              for survival time prediction of brain tumor patients using multi‐modal   between  radiation-induced  brain  injury  and  glioma  recurrence[J].  Eur
              neuroimages[J/OL].  Sci  Rep,  2019,  9(1):  1103  [2024-03-04].  https://  Radiol, 2023, 33(5): 3332-3342. DOI: 10.1007/s00330-022-09365-3.
              pubmed.ncbi.nlm.nih.gov/30705340/. DOI: 10.1038/s41598-018-37387-9.  [65] REN J F, ZHAI X Y, YIN H J. Multimodality MRI radiomics based on
           [51] TANG Z, XU Y, JIN L, et al.  Deep learning of imaging phenotype and   machine learning for identifying true tumor recurrence and treatment-related
              genotype  for  predicting  overall  survival  time  of  glioblastoma  patients[J].   effects in patients with postoperative glioma[J]. Neurol Ther, 2023, 12(5):
              IEEE  Trans  Med  Imaging,  2020,  39(6):  2100-2109.  DOI:  10.1109/  1729-1743. DOI: 10.1007/s40120-023-00524-2.
              TMI.2020.2964310.                                [66] MANA M, SHAHRIAR F, GIAN M C, et al. A deep learning model for
           [52] CHAE J P,  KYUNGHWA H,  HWIYOUNG K, et al. Radiomics risk   discriminating  true  progression  from  pseudoprogression  in  glioblastoma
              score may be a potential imaging biomarker for predicting survival in   patients[J]. J Neurooncol, 2022, 159(2): 447-455. DOI: 10.1007/s11060-
              isocitrate dehydrogenase wild-type lower-grade gliomas[J]. Eur Radiol,   022-04080-x.
              2020, 30(12): 6464-6474. DOI: 10.1007/s00330-020-07089-w.  [67] CHOI  S,  YU  Y,  GRIMMER  M  R,  et  al.  Temozolomide-associated
           [53] VERDUGO E, PUERTO I, MEDINA M Á. An update on the molecular   hypermutation  in  gliomas[J].  Neuro  Oncol,  2018,  20(10):  1300-1309.
              biology  of  glioblastoma,  with  clinical  implications  and  progress  in  its   DOI: 10.1093/neuonc/noy016.
              treatment[J]. Cancer Commun, 2022, 42(11): 1083-1111. DOI: 10.1002/  [68] CRAIG H,  LOUIS B N, JANA P, et al. NCCN guidelines(R) insights:
              cac2.12361.                                          central nervous system cancers, version 2.2022[J]. J Natl Compr Canc
           [54] MALMSTRÖM  A,  ŁYSIAK  M,  ÅKESSON  L,  et  al.  ABCB1   Netw, 2023, 21(1): 12-20. DOI: 10.6004/jnccn.2023.0002.
              single-nucleotide  variants  and  survival  in  patients  with  glioblastoma  treated   [69] GRAMATZKI  D,  ROTH  P,  RUSHING  E  J,  et  al.  Bevacizumab  may
              with radiotherapy concomitant with temozolomide[J]. Pharmacogenomics J,   improve  quality  of  life,  but  not  overall  survival  in  glioblastoma:  an
              2020, 20(2): 213-219. DOI: 10.1038/s41397-019-0107-z.  epidemiological  study[J].  Ann  Oncol,  2018,  29(6):  1431-1436.  DOI:
           [55] KELLY  C,  MAJEWSKA  P,  IOANNIDIS  S,  et  al.  Estimating   10.1093/annonc/mdy106.
              progression-free survival in patients with glioblastoma using routinely   [70] LI Y  R,  XU  W  L,  FEI Y  L,  et  al. A  MRI-based  radiomics  model  for
              collected data[J]. J Neurooncol, 2017, 135(3): 621-627. DOI: 10.1007/  predicting  the  response  to  anlotinb  combined  with  temozolomide  in
              s11060-017-2619-1.                                   recurrent  malignant  glioma  patients[J/OL].  Discov  Oncol,  2023,  23,
           [56] DAYTON  G,  DAVID  P,  MEGAN  C,  et  al.  Clinical  and  radiographic   14(1): 154 [2024-03-04]. https://pubmed.ncbi.nlm.nih.gov/37612579/.
              characteristics  of  diffuse  astrocytic  glioma,  IDH-wildtype,  with  molecular   DOI: 10.1007/s12672-023-00751-x.
              features of glioblastoma: a single institution review[J]. J Neurooncol, 2022,   [71] WEI  J  W,  YANG  G  G,  HAO  X  H, et  al.  A  multi-sequence  and
              157(1): 187-195. DOI: 10.1007/s11060-022-03961-5.    habitat-based  MRI  radiomics  signature  for  preoperative  prediction  of
           [57] PARK C J, HAN K, KIM H, et al. MRI features may predict molecular   MGMT  promoter  methylation  in  astrocytomas  with  prognostic
              features of glioblastoma in isocitrate dehydrogenase wild-type lower-grade   implication[J].  Eur  Radiol,  2019,  29(2):  877-888.  DOI:  10.1007/
              gliomas[J]. AJNR Am J Neuroradiol, 2021, 42(3): 448-456. DOI: 10.3174/  s00330-018-5575-z.
              ajnr.A6983.                                      [72] BOBHOLZ  S  A,  HOEFS  A,  HAMBURGER  J,  et  al.  Radio-pathomic
           [58] XIN  K,  YU  M,  YU  Q  L,  et  al.  Machine  learning  models  based  on   maps  of  glioblastoma  identify  phenotypes  of  non-enhancing  tumor
              multi-parameter  MRI  radiomics  for  prediction  of  molecular   infiltration  associated  with  bevacizumab  treatment  response[J].  J
              glioblastoma:  a  new  study  based  on  the  2021  World  Health  Organization   Neurooncol, 2024, 167(2): 233-241. DOI: 10.1007/s11060-024-04593-7.
              classification[J]. Acta Radiol, 2023, 64(11): 2938-2947. DOI: 10.1177/  [73] WANG  H,  XU  T,  HUANG  Q,  et  al.  Immunotherapy  for  malignant
              02841851231199744.                                   glioma: Current status and future directions[J]. Trends Pharmacol Sci,
           [59] YAE W P,  SOOYON K, CHAE J, et al. Adding radiomics to the 2021   2020, 41(2): 123-138. DOI: 10.1016/j.tips.2019.12.003.
              WHO  updates  may  improve  prognostic  prediction  for  current   [74] KE Y Y, ZHI J W,  HAO Z, et al. Glioma targeted therapy: insight into
              IDH-wildtype  histological  lower-grade  gliomas  with  known  EGFR   future  of  molecular  approaches[J/OL].  Mol  Cancer,  2022,  21(1):  39
              amplification and TERT promoter mutation status[J]. Eur Radiol, 2022,   [2024-03-04]. https://pubmed.ncbi.nlm.nih.gov/35135556/. DOI: 10.1186/
              32(12): 8089-8098. DOI: 10.1007/s00330-022-08941-x.  s12943-022-01513-z.
           [60] FUJIMOTO K, ARITA H, SATOMI K, et al. TERT promoter mutation   [75] DAPASH  M,  HOU  D,  CASTRO  B,  et  al.  The  interplay  between
              status  is  necessary  and  sufficient  to  diagnose  IDH-wildtype  diffuse   glioblastoma and its microenvironment[J/OL]. Cells, 2021, 10(9): 2257
              astrocytic  glioma  with  molecular  features  of  glioblastoma[J].  Acta   [2024-03-04]. https://pubmed.ncbi.nlm.nih.gov/34571905/. DOI: 10.3390/
              Neuropathol, 2021, 142(2): 323-338. DOI: 10.1007/s00401-021-02337-9.  cells10092257.
           [61] DU P, WU X F, LIU X, et al. Establishment of a prediction model based   [76] CHEN  D,  ZHANG  R,  HUANG  X,  et  al.  MRI-derived  radiomics
              on  preoperative  MRI  radiomics  for  diffuse  astrocytic  glioma,   assessing  tumor-infiltrating  macrophages  enable  prediction  of
              IDH-wildtype, with molecular features of glioblastoma[J/OL]. Cancers   immune-phenotype, immunotherapy response and survival in glioma[J/OL].
              (Basel), 2023, 15(20): 5094 [2024-03-04]. https://pubmed.ncbi.nlm.nih.  Biomark Res, 2024, 12(1): 14 [2024-03-04]. https://pubmed.ncbi.nlm.
              gov/37894461/. DOI: 10.3390/cancers15205094.         nih.gov/38291499/. DOI: 10.1186/s40364-024-00560-6.
           [62] PARK  Y  W,  CHOI  D,  PARK  J  E,  et  al.  Differentiation  of  recurrent   [77] LUAN J, ZHANG D, LIU B, et al. Immune-related lncRNAs signature
              gli-oblastoma  from  radiation  necrosis  using  diffusion  radiomics  with   and   radiomics   signature   predict   the   prognosis   and   immune
              machine  learning  model  development  and  external  validation[J/OL].   microenvironment  of  glioblastoma  multiforme[J/OL]. J  Transl  Med,  2024,
              Sci Rep, 2021, 11(1): 2913 [2024-03-04]. https://pubmed.ncbi.nlm.nih.  22(1): 107 [2024-03-04]. https://pubmed.ncbi.nlm.nih.gov/38279111/.
              gov/33536499/. DOI: 10.1038/s41598-021-82467-y.      DOI: 10.1186/s12967-023-04823-y.

























          ·172 ·                                                                      https://www.chinesemri.com
   174   175   176   177   178   179   180   181   182   183   184